Melatonin effect on platelet count in patients with liver disease

Area of Science:

• Hepatology and Gastroenterology
• Endocrinology
• Hematology

Background:

• Thrombocytopenia is a common complication of advanced chronic liver disease.
• Reduced thrombopoietin secretion by the liver contributes to liver disease-induced thrombocytopenia.
• Melatonin's potential role in managing liver disease complications is under investigation.

Purpose of the Study:

• To evaluate the effect of melatonin on platelet count in patients with chronic liver disease.
• To assess melatonin's impact on liver function tests and MELD scores.

Main Methods:

• A double-blind, cross-over, placebo-controlled pilot study design.
• Patients received melatonin (10 mg/day) or placebo for two weeks, followed by a two-week washout period and group switch.
• Platelet counts and liver function tests were assessed at baseline and study end.

Main Results:

• Melatonin significantly increased platelet counts compared to placebo (p < 0.001).
• Melatonin administration led to significant reductions in ALT, AST, total bilirubin, and direct bilirubin levels.
• MELD scores were also significantly reduced following melatonin treatment (p < 0.05).

Conclusions:

• Melatonin may effectively increase platelet count and mitigate thrombocytopenia in chronic liver disease patients.
• Melatonin demonstrates potential benefits for liver function and disease severity.
• Further research is warranted to confirm these findings and establish melatonin's therapeutic efficacy.